CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 695 enrolled
Drug / intervention
Comparator: Varicella Zoster Virus Vaccine +1 morebiological
Likely dose
Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (~207,000 plaque-forming units [PFU]/0.65-mL dose)AI-extracted
Key inclusion· 3
  • ✓Age 50 years or older
  • ✓History of chickenpox
  • ✓No prior herpes zoster infection
Key exclusion· 1
  • ✕Preexisting conditions that inhibit immune response

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00092417
NCT00092417Phase 3Completed
CompareCT.gov

Evaluation of the Safety and Tolerability of a Higher Potency Dose of Varicella Zoster Virus Vaccine Live (Oka/Merck)Among Adults 50 Years of Age or Older

Merck Sharp & Dohme LLC·interventional·Posted Sep 27, 2004·Updated Oct 7, 2015

In Brief

A Phase 3 clinical trial evaluating Comparator: Varicella Zoster Virus Vaccine for Healthy. Completed, enrolled 695 participants.

Detailed Summary

This study compared the safety and tolerability profile of a higher potency investigational vaccine to that of the investigational vaccine at a lower potency dose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 27, 2004
Enrollment StartOct 1, 2003
Primary CompletionJun 1, 2004
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 21.8 years ago

Interventions

Comparator: Varicella Zoster Virus Vaccinebiological

Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (\~207,000 plaque-forming units \[PFU\]/0.65-mL dose)

Comparator: Varicella Zoster Virus Vaccinebiological

Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (\~58,000 plaque-forming units \[PFU\]/0.65-mL dose)